By Sabela Ojea


AstraZeneca PLC said Thursday that its Farxiga drug showed positive results from the Deliver and Dapa-HF Phase 3 trial in reducing the risk of cardiovascular death or worsening heart failure.

The Anglo-Swedish pharma giant said that the trial was conducted in patients suffering from heart failures with mildly reduced or preserved ejection fraction.

"The safety and tolerability profile of Farxiga in the Deliver Phase 3 trial were consistent with the well-established safety profile of the medicine," it added.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

05-05-22 0242ET